文献速递肝病消化道肿瘤与早癌

肝细胞癌的表观遗传治疗:新兴临床工具与应用

Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications.
PubMed 文献 · Gut · 2026-07-08

肝细胞癌(HCC)晚期现有疗法疗效有限,多数病例在慢性肝病尤其肝硬化背景下发生,炎症、肝细胞死亡与再生的循环促进遗传与表观遗传改变累积。本综述面向临床医生与研究者,汇总已完成的与正在进行的「表观遗传药物」临床试验结果,讨论靶向表观遗传机制既可能抑制肿瘤生长,也可能通过逆转耐药通路增强现有疗法效果。

要点

  • 表观遗传失调是HCC肿瘤进展与治疗耐药的关键驱动因素。
  • 表观遗传药物(epidrugs)的已完成与在研临床试验结果被系统汇总。
  • 靶向表观遗传机制有望抑制肿瘤并逆转耐药、增强现有疗法疗效。

核心结论

  • 表观遗传失调是HCC肿瘤进展和治疗耐药的关键驱动因素,构成新的干预前沿。
  • 靶向表观遗传机制不仅可能抑制肿瘤生长,还可能通过逆转耐药通路增强现有疗法的有效性。
  • 表观遗传学有望重塑HCC管理格局,带来更持久和个体化的治疗反应。

研究设计与样本

  • 综述类文章:汇总HCC表观遗传治疗领域已完成和正在进行的涉及表观遗传药物(epidrugs)的临床试验结果。
  • 面向临床医生与研究者,将复杂分子见解转化为可操作的治療策略。

主要发现

  • HCC是全球第二大癌症死亡原因,主要因晚期现有疗法疗效有限。
  • 多数HCC发生于慢性肝病尤其肝硬化背景,炎症、肝细胞死亡与再生的持续循环促进遗传与表观遗传改变逐步累积。
  • 这些分子改变促成HCC高度肿瘤异质性,是当前治疗耐药的主要因素。
  • 酪氨酸激酶抑制剂、抗血管生成药物和免疫检查点抑制剂等现有疗法持续临床反应仍不常见。

临床怎么用

  • 临床医生可关注表观遗传药物临床试验进展,作为晚期HCC潜在的新治疗方向。
  • 表观遗传治疗策略可考虑与现有疗法联合,以逆转耐药通路、增强疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide, largely due to the limited efficacy of current therapies in advanced stages of the disease. Most cases of HCC develop in the setting of chronic liver disease, particularly cirrhosis, where ongoing cycles of inflammation, hepatocyte death and regeneration foster the gradual accumulation of genetic and epigenetic alterations that promote malignant transformation. These molecular changes contribute to the high degree of tumour heterogeneity observed in HCC, a major factor underlying resistance to current treatments. As a result, sustained clinical responses to existing therapies, such as tyrosine kinase inhibitors, anti-angiogenic agents and immune checkpoint inhibitors, remain uncommon. In this context, a growing body of evidence has identified epigenetic dysregulation as a key driver of tumour progression and therapeutic resistance, highlighting a new frontier for intervention. This review provides clinicians and researchers with a comprehensive overview of the emerging field of epigenetic therapies in HCC, summarising results from both completed and ongoing clinical trials involving the so-called 'epidrugs'. Importantly, we discuss how targeting epigenetic mechanisms may not only suppress tumour growth but also enhance the effectiveness of current therapies by reversing resistance pathways. By translating complex molecular insights into tangible therapeutic strategies, epigenetics is poised to reshape the future of HCC management, offering renewed hope for more durable and personalised treatment responses in a disease where progress is urgently needed.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Bueloni B, G Fernandez-Barrena M, Fiore E, et al. Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications. Gut. 2026. PMID: 40987534. doi:10.1136/gutjnl-2025-336317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。